Highly Systemic Metastatic Cell Line (VM-M2) from KERAFAST, INC.

Search, find, compare suppliers for Highly Systemic Metastatic Cell Line (VM-M2) products.

Edit 
Product NameHighly Systemic Metastatic Cell Line (VM-M2)
DescriptionSource: Mouse Brain. Cell type: VM-M2 & VM-M3: Malignant Histiocytoma, VM-NM1: Malignant Astrocytoma.
Size1 vial
Concentrationn/a
Applicationsn/a
Other Namesn/a
Gene, Accession, CAS #Accession: VM-M2/Fluc, CVCL_0P41; VM-M3/Fluc, CVCL_0P42; VM-NM1/Fluc, CVCL_0P43
Catalog #EBC001
Price$658
Order / More InfoHighly Systemic Metastatic Cell Line (VM-M2) from KERAFAST, INC.
Product Specific References
  1. Poff AM, Ward N, Seyfried TN, Arnold P, D'Agostino DP. Non-Toxic Metabolic Management of Metastatic Cancer in VM Mice: Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy. PLoS One. 2015 Jun 10;10(6):e0127407.
  2. Poff AM, Ari C, Seyfried TN, D'Agostino DP. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One. 2013 Jun 5;8(6):e65522.
  3. Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18(1-2):43-73.
  4. Strelko CL, Lu W, Dufort FJ, Seyfried TN, Chiles TC, Rabinowitz JD, Roberts MF. Itaconic acid is a mammalian metabolite induced during macrophage activation. J Am Chem Soc. 2011 Oct 19;133(41):16386-9.
  5. Huysentruyt LC, Akgoc Z, Seyfried TN. Hypothesis: are neoplastic macrophages/microglia present in glioblastoma multiforme?ASN Neuro. 2011 Sep 22;3(4).
  6. Huysentruyt LC, Seyfried TN. Perspectives on the mesenchymal origin of metastatic cancer. Cancer Metastasis Rev. 2010 Dec;29(4):695-707.
  7. Shelton LM, Huysentruyt LC, Mukherjee P, Seyfried TN. Calorie restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. ASN Neuro. 2010 Jul 23;2(3):e00038.
  8. Shelton LM, Huysentruyt LC, Seyfried TN. Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. Int J Cancer. 2010 Nov 15;127(10):2478-85.
  9. Shelton LM, Mukherjee P, Huysentruyt LC, Urits I, Rosenberg JA, Seyfried TN. A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. J Neurooncol. 2010 Sep;99(2):165-76.
  10. Huysentruyt LC, Shelton LM, Seyfried TN. Influence of methotrexate and cisplatin on tumor progression and survival in the VM mouse model of systemic metastatic cancer. Int J Cancer. 2010 Jan 1;126(1):65-72.
  11. Huysentruyt LC, Mukherjee P, Banerjee D, Shelton LM, Seyfried TN. Metastatic cancer cells with macrophage properties: evidence from a new murine tumor model. Int J Cancer. 2008 Jul 1;123(1):73-84.
KERAFAST, INC.
KERAFAST, INC.
KERAFAST, INC.
An Absolute Biotech Company
2 Shaker Road, Unit B101
Shirley MA 01464
P: +1-617-336-3228
P: +1-800-546-1760
F: +1-866-727-9826

info@kerafast.com
Tech Support: TechnicalSupport@kerafast.com

https://www.kerafast.com

Profile of KERAFAST, INC.

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.